Founded in 2008 and headquartered in Nyon, Switzerland, MedAlliance specializes in the development and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. Using proprietary technology, MedAlliance has developed SELUTION SLR, a drug-eluting balloon catheter with sustained limus release technology, for the treatment of both coronary and peripheral artery disease. SELUTION SLR's technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus, providing controlled and sustained release of the drug. In 2019, MedAlliance became the first DEB company to receive Breakthrough Device Designation Status from the FDA for a coronary DEB, and SELUTION SLR has achieved this status for a range of indications. In 2020, MedAlliance received CE Mark Approval for SELUTION SLR in the treatment of peripheral arterial disease and SELUTION SLR 014 PTCA for the treatment of coronary arterial disease.